Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04018092 · ClinicalTrials.gov registry record · Phase 2

The Revitalize Study in Older Adults at Risk for Alzheimer's Disease

A Phase 2 study of Cognitive Aging and Alzheimer Disease, Protection Against, sponsored by University of Florida.

Active
Registry status
Phase 2
Development phase
168
Enrollment target
2
Study locations

NCT04018092 is a Phase 2 study of Cognitive Aging and Alzheimer Disease, Protection Against that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 168 participants, below the 501-participant average among 5 other Cognitive Aging trials with a reported enrollment target (66% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04018092, a Phase 2 study of Cognitive Aging and Alzheimer Disease, Protection Against, is active but no longer recruiting, sponsored by University of Florida.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
168 participants
Enrollment target
2
Study locations

Study Summary

The goal of this multi-site double blinded randomized sham-controlled Phase II clinical trial is to test a novel, relatively low cost, low risk, and potentially high impact therapeutic intervention in older adults who are at increased risk for Alzheimer's disease. The intervention involves transcranial and intranasal delivery of near infrared (NIR) light via light emitting diodes, aka photobiomodulation (PBM). The overall hypothesis, based on animal and pilot studies, is that exposure to NIR stimulation will have beneficial effects on brain health via influence on mitochondrial function as measured by changes in 31Phosphorous (31P) MRS-based markers of ATP, neural network changes in functional connectivity (rs-fMRI), and improved cognitive performance. To test this hypothesis, 168 older adults with subjective cognitive complaints, and a first-degree family history of Alzheimer's disease will be randomized to sham or real treatment groups. Neuroimaging and cognitive outcome measures will be obtained, before and after a 12-week intervention involving transcranial and intranasal NIR-PBM. The intervention protocol will involve "lab" and "home" sessions, and a 3 month post-intervention follow-up. This trial will determine: 1) whether NIR stimulation, relative to sham, improves performance on memory and executive tasks sensitive to hippocampal and frontal brain function in older adults with increased risk for Alzheimer's disease; 2) whether NIR stimulation, relative to sham, enhances brain function and connectivity measured by changes in MRS phosphorous ATP and resting state functional connectivity; and 3) how differences in demographic, neuroimaging, and Alzheimer-related risk factors influence the brain response to NIR stimulation versus sham in older adults with increased risk for Alzheimer's disease. Results will provide key insights into whether this novel NIR intervention can enhance cognition in older adults with increased risk for Alzheimer's disease and will prov

Interventions

  • DEVICE Active NIR-PBM
  • DEVICE Sham NIR-PBM

Study Locations (2)

Arizona

  • University of Arizona - Tucson

Florida

  • University of Florida McKnight Brain Institute - Gainesville

Trial Details

FieldValue
Enrollment Target 168 participants
Start Date 2020-08-12
Est. Completion 2026-06-30
Phase Phase 2

Sponsor

University of Florida

1,106 total trials

What the Registry Record Tells You About NCT04018092

The ClinicalTrials.gov registry entry for NCT04018092 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 501-participant average among 5 other Cognitive Aging trials with a reported enrollment target (66% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cognitive Aging appearing as the primary indexed condition, and to 2 interventions - of which Active NIR-PBM is the first listed.

NCT04018092 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT04018092 about?

NCT04018092 is a clinical study titled "The Revitalize Study in Older Adults at Risk for Alzheimer's Disease". The goal of this multi-site double blinded randomized sham-controlled Phase II clinical trial is to test a novel, relatively low cost, low risk, and potentially high impact therapeutic intervention in older adults who are at increased risk for Alzheimer's disease. The intervention involves transcran...

What is the current status of trial NCT04018092?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2020-08-12. Estimated completion is 2026-06-30.

What conditions does trial NCT04018092 study?

This clinical trial studies the following conditions: Cognitive Aging, Alzheimer Disease, Protection Against.

What interventions are being tested in trial NCT04018092?

The interventions under investigation include: Active NIR-PBM (DEVICE), Sham NIR-PBM (DEVICE).

Who is sponsoring clinical trial NCT04018092?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04018092 being conducted?

This trial has 2 study locations across Arizona, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cognitive Aging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.